LAUSR

The effect of two bone-forming agents — the anti-slerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been receiving bisphosphonate therapy. Change from baseline in total hip areal bone mineral density through 12 months was higher in patients who received romosozumab 210 mg once monthly compared with those treated with teriparatide 20 μg once daily (2.6% versus –0.6%).